AUTH/3525/6/21 - Complainant v Novo Nordisk

Concerns about sponsored courses offered on LinkedIn

  • Received
    22 June 2021
  • Case number
    AUTH/3525/6/21
  • Applicable Code year
    2019
  • Completed
    15 March 2025
  • Breach Clause(s)
  • Sanctions applied
    Undertaking received
  • Additional sanctions
    Advertisement
    Public reprimand
    Audit of company’s procedures
    Reports to ABPI Board
    Suspended from membership of the ABPI
  • Appeal
    Appeal by the respondent

Case Summary

This case was in relation to Novo Nordisk’s sponsorship of weight management courses for health professionals, including the funding of the Patient Group Direction (PGD) for Saxenda (liraglutide). The complainant made several allegations including that Novo Nordisk’s involvement in, and the promotional nature of, the training was not clear from the LinkedIn post, and that the provision of the PGD was of benefit to individual health professionals and an inducement to prescribe.

The outcome under the 2019 Code was:

Breach of Clause 2[Panel’s breach ruling upheld at appeal]

Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Breach of Clause 9.1 (x2[Panel’s breach ruling upheld at appeal]

Failing to maintain high standards and secondly for failing to certify promotional material

Breach of Clause 4.1[Panel’s breach ruling upheld at appeal]

Failing to include prescribing information

Breach of Clause 9.10

Failing to indicate, at the outset, that the training and offer of PGDs was sponsored by Novo Nordisk

Breach of Clause 12.1[Panel’s breach ruling upheld at appeal]

Disguised promotion

Breach of Clause 18.1[Panel’s breach ruling upheld at appeal]

Offering a benefit to individual health professionals that did not meet the requirements of the Code and was considered an inducement to prescribe, supply, administer and/or recommend Saxenda

Breach of Clause 22.4

Failing to disclose, at the outset, in all of the papers relating to the meetings that the training had been sponsored by Novo Nordisk

The Appeal Board publicly reprimanded Novo Nordisk for its failings and the potential impact on patient safety. The Appeal Board additionally reported the company to the ABPI Board, which required an audit of Novo Nordisk’s procedures in relation to the Code. Following that audit, the ABPI Board decided to suspend Novo Nordisk from membership of the ABPI for a period of 2 years. The suspension was subject to several conditions, including PMCPA re-audits in late 2023 and 2024.

In April 2024, following its review of the PMCPA re-audit report, the ABPI Board acknowledged the progress the company had made but raised serious concerns about Novo Nordisk’s culture, the speed and seriousness with which the company was acting, and whether the case and suspension had been taken seriously enough at a global level within the organisation.

In March 2025, following its review of the latest PMCPA re-audit report, the ABPI Board decided that Novo Nordisk now had the systems and culture in place to give the ABPI Board confidence that the company could resume engagement as a responsible member of self-regulation. ABPI Board members unanimously voted in favour of Novo Nordisk reengaging as a full member of the ABPI.


This summary is not intended to be read in isolation.
For full details, please see the full case report below.